Related Experiment Video
Updated: Jul 16, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human
Bo Xie1, Juntao Lin1, Xianwu Chen1
1Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, R.P. China.
Background:
Bladder cancer (BCa) is the fourth most common malignant tumor with a poor prognosis worldwide. Further exploration and research are needed to unmask the underlying roles and molecular mechanisms of circular RNAs. In the current study, our findings showed that circXRN2 suppresses tumor progression driven by histone lactylation by activating the Hippo pathway in human bladder cancer.
Methods:
RNA immunoprecipitation (RIP) followed by circRNA sequencing confirmed circXRN2 as the research object. Overexpression of circXRN2 and knockdown of TAZ/YAP further verified the biological functions in T24 and TCCSUP cells. RIP, immunoprecipitation and coimmunoprecipitation were used to elucidate the interaction between circXRN2 and LATS1. A Seahorse metabolic analyzer was used to determine the glycolytic rate. Cleavage under targets and Tagmentation (CUT&Tag) and chromatin immunoprecipitation (ChIP) were employed to ensure the regulatory roles of H3K18 lactylation in the transcriptional activity of LCN2.
Results:
CircXRN2 is aberrantly downregulated in bladder cancer tissues and cell lines. CircXRN2 inhibits the proliferation and migration of tumor cells both in vitro and in vivo. In addition, circXRN2 serves as a negative regulator of glycolysis and lactate production. Mechanistically, circXRN2 prevents LATS1 from SPOP-mediated degradation by binding to the SPOP degron and then activates the Hippo signaling pathway to exert various biological functions. The circXRN2-Hippo pathway regulatory axis further modulates tumor progression by inhibiting H3K18 lactylation and LCN2 expression in human bladder cancer.
Conclusions:
CircXRN2 suppresses tumor progression driven by H3K18 lactylation by activating the Hippo signaling pathway in human bladder cancer. Our results indicated novel therapeutic targets and provided promising strategies for clinical intervention in human bladder cancer.
Insights
Circular RNA XRN2 (circXRN2) suppresses bladder cancer progression by activating the Hippo pathway and inhibiting histone lactylation. This discovery offers new therapeutic strategies for bladder cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Bladder cancer (BCa) is a prevalent malignancy with a poor prognosis.
- Circular RNAs (circRNAs) are increasingly recognized for their roles in cancer, but their specific functions in BCa require further elucidation.
- Histone lactylation is an emerging epigenetic modification implicated in tumorigenesis.
Purpose of the Study:
- To investigate the role of circXRN2 in bladder cancer progression.
- To explore the molecular mechanisms by which circXRN2 influences tumor growth, focusing on the Hippo pathway and histone lactylation.
- To identify potential therapeutic targets for bladder cancer.
Main Methods:
- RNA immunoprecipitation (RIP) and circRNA sequencing to identify and validate circXRN2.
- Cellular and in vivo experiments (overexpression/knockdown) to assess circXRN2 function.
- Co-immunoprecipitation, CUT&Tag, and ChIP assays to elucidate molecular interactions and regulatory roles.
- Seahorse metabolic analysis to evaluate cellular metabolism.
Main Results:
- CircXRN2 is downregulated in bladder cancer tissues and cell lines.
- CircXRN2 inhibits tumor cell proliferation and migration in vitro and in vivo.
- CircXRN2 negatively regulates glycolysis and lactate production.
- CircXRN2 prevents LATS1 degradation, activating the Hippo pathway.
- The circXRN2-Hippo pathway axis inhibits H3K18 lactylation and LCN2 expression, suppressing bladder cancer progression.
Conclusions:
- CircXRN2 acts as a tumor suppressor in bladder cancer by activating the Hippo pathway and inhibiting H3K18 lactylation-driven tumor progression.
- The circXRN2-Hippo pathway offers a novel regulatory axis with potential as a therapeutic target for bladder cancer.
More Related Videos
Related Concept Videos
lncRNA - Long Non-coding RNAs
Inheritance of Chromatin Structures
Abnormal Proliferation
Hedgehog Signaling Pathway
Epigenetic Regulation
X-chromosome...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

